Novartis Ag (NVS) Receivables - Net (2009 - 2026)
Novartis Ag (NVS) posted Receivables - Net of $9.6 billion for Q2 2026, up 7.82% sequentially from $8.9 billion in Q4 2025, and up 6.4% YoY from $9.1 billion in Q2 2025.
Novartis Ag (NVS) Receivables - Net (2009 - 2026) Analysis & Trends
Novartis Ag has reported Receivables - Net for 18 years, with the latest figure at $9.6 billion in Q2 2026.
- Quarterly Receivables - Net rose 6.4% year-over-year to $9.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.6 billion (up 6.4% YoY) and the FY2025 annual result came in at $8.9 billion, up 20.4% from the prior year.
- Receivables - Net improved to $9.6 billion in Q2 2026 per NVS's latest filing, from $8.9 billion in the prior quarter.
- Over five years, Receivables - Net peaked at $9.6 billion in Q2 2026 and troughed at $7.1 billion in Q4 2023.
- A 5-year average of $8.5 billion and a median of $8.6 billion in 2022 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2023 and 2025: Receivables - Net fell 11.89% in 2023, then rose 20.4% in 2025.
- Over 5 years, Receivables - Net stood at $8.1 billion in 2022, then declined by 11.89% to $7.1 billion in 2023, then grew by 4.45% to $7.4 billion in 2024, then gained by 20.4% to $8.9 billion in 2025, then increased by 7.82% to $9.6 billion in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $9.6 billion, $8.9 billion, and $9.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.03 Bn | 634.27 Bn | 17.26 Bn |
| 2 | AbbVie | 470.29 Bn | 463.72 Bn | 12.70 Bn |
| 3 | Merck | 380.80 Bn | 373.66 Bn | 12.21 Bn |
| 4 | Novartis Ag | 302.80 Bn | 295.11 Bn | 11.24 Bn |
| 5 | Astrazeneca | 258.24 Bn | 253.34 Bn | 12.86 Bn |
| 6 | Amgen | 237.40 Bn | 223.41 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.07 Bn | 179.89 Bn | 6.22 Bn |
| 8 | Pfizer | 161.54 Bn | 149.84 Bn | 10.94 Bn |
| 9 | Gsk | 106.01 Bn | 101.85 Bn | 8.24 Bn |
| 10 | Sanofi | 55.05 Bn | 47.67 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.64 Bn |
| Jun 30, 2026 | 9.64 Bn |
| Dec 31, 2025 | 8.94 Bn |
| Dec 31, 2025 | 8.94 Bn |
| Jun 30, 2025 | 9.06 Bn |
| Jun 30, 2025 | 9.06 Bn |
| Dec 31, 2024 | 7.42 Bn |
| Dec 31, 2024 | 7.42 Bn |
| Jun 30, 2024 | 8.23 Bn |
| Jun 30, 2024 | 8.23 Bn |
| Dec 31, 2023 | 7.11 Bn |
| Dec 31, 2023 | 7.11 Bn |
| Jun 30, 2023 | 9.20 Bn |
| Jun 30, 2023 | 9.20 Bn |
| Dec 31, 2022 | 8.07 Bn |
| Dec 31, 2022 | 8.07 Bn |
| Jun 30, 2022 | 8.64 Bn |
| Jun 30, 2022 | 8.64 Bn |
| Dec 31, 2021 | 8.01 Bn |
| Dec 31, 2021 | 8.01 Bn |